What does Donald Trump’s former commerce secretary Wilbur Ross mean when he says in Dublin that pharmaceutical companies “gradually come around”? The answer, if correct, is reassuring for Ireland.
London-based CapVest, founded in 1999, is led by Irishman Seamus Fitzpatrick. While the private-equity firm has completed multiple deals in excess of €1 billion, this would be its largest yet.
How should a pharma multinational respond to the uncertainty unleashed by the Trump administration? Invest more in Ireland, the contact-lens and eye-drop giant appears to have decided.
The company terminated its Dublin lease in December as it shifts its focus away from the European market. It has been gradually winding down the Irish base.
Multinationals led by pharmaceutical manufacturers have long used intangible assets and transfer pricing to shift profits to Ireland. Could the same moves work in reverse to reduce exposure to tariffs?
The pharma firm is building a drug manufacturing site in Dublin, due for completion next year, and has been piling several tranches of capital into a new subsidiary to manage it.
The healthcare industry and its supply chain are both first responders to the illnesses and injuries caused by global warming and a major source of greenhouse gas emissions, holding major potential to address the crisis.
Behind a veil of prudence, Government projections continue to forecast rapid growth in corporation tax revenue. For another week, they appear not to be wrong.
Ireland hosts several international pharmaceutical giants and the companies are keen to get their voices heard in Brussels via Ireland.
Founded by the North’s first Chief Scientific and Technology Adviser Professor Helen McCarthy, Phion Therapeutics had a pipeline of exciting treatments. But now administrators have been appointed to the firm, which is backed by a Hong Kong top-40 pharmaceutical company.
© 2025 Currency Media Limited
